Skip to search formSkip to main contentSkip to account menu

CDP870

Known as: CDP870s, 870s, CDP, 870, CDP 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

certolizumab pegol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
BACKGROUND TNF-alpha inhibitors have been shown to reduce the risk of joint damage and improve physical function and quality of… 
Review
2010
Review
2010
TNF-α and its inhibitors in cancer
Tumor necrosis factor (TNF)-α is implicated in the same time in apoptosis and in cell proliferation. TNF-α not only acts as pro… 
Review
2009
Review
2009
Certolizumab pegol for the management of Crohn's disease in adults.
Review
2007
Review
2007
Targeting nanomedicines in the treatment of Crohn’s disease: focus on certolizumab pegol (CDP870)
A variety of targets for therapeutic intervention are based upon advances in understanding of the immunopathogenesis of Crohn’s… 
Highly Cited
2005
Highly Cited
2005
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.
BACKGROUND & AIMS To investigate the efficacy and safety of certolizumab pegol (a polyethylene-glycolated Fab' fragment of anti… 
2005
2005
In Vitro Complement-Dependent Cytotoxicity and Antibody-Dependent Cellular Cytotoxicity by the Anti-TNF Agents Adalimumab, Etanercept, Infliximab, and Certolizumab Pegol (CDP870): 807
Highly Cited
2004
Highly Cited
2004
Pharmaceutical profiling in drug discovery for lead selection
Absorption Prediction.- Predicting Molecular Physical Properties.- In Silico Transporter Modeling and Its Application in Drug… 
Review
2004
Review
2004
Biologics in inflammatory bowel disease: how much progress have we made?
Biologic therapies include:(1) naturally occurring or modified biologic compounds such as vaccines (live, live attenuated, or… 
Review
2003
Review
2003
Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease
The introduction of infliximab, a mouse/human chimeric monoclonal antibody to tumor necrosis factor (TNF), is an important… 
2003
2003
Fecal lactoferrin measurements are useful in the interval assessment of patients with active and inactive inflammatory bowel disease
Fecal lactoferrin measurements are useful in the interval assessment of patients with active and inactive inflammatory bowel… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)